



2022 Corporate Sustainability Report

**Committed to
doing our part**

PTC's commitment to corporate responsibility focuses on five key areas:
**our patients, our people, our community,
our environment and our values.**

Table of Contents

Who We Are

Our Science
 Our Therapeutic Areas
 Research & Development
 Products & Pipeline
 Awards & Recognition

Patients

Patient Advocacy
 Support for the Rare Disease Community
 Clinical Trials
 Support for Patient Communities & Access to Care

People

Culture & Expectations
 Talent Planning
 Global Onboarding
 Benefits & Wellbeing
 Building a Strengths-Based Learning Culture

Community

Our Culture & Community
 Global Equality, Diversity & Inclusion
 Global Employee Outreach
 Community Enrichment

Environment

Green Operations
 Sustainability Efforts

Ethics & Compliance

Compliance Program
 Code of Business Conduct & Ethics
 Privacy Policies & Cybersecurity
 Board of Directors



At PTC, we are mission driven. We don't just work for a company; we work for a cause. Patients first, always. Since our founding in 1998, we have focused on doing the right thing for our stakeholders, and now as a global biopharmaceutical company we take our obligations related to environmental stewardship, social responsibility, and corporate governance seriously. Building on and improving efforts in these areas is crucially important to our continued success as a company. **Our deep passion for patients drives us to think differently about solutions and to work collaboratively as One PTC.** With our continued focus on this mission and steadfast commitment to retaining our unique culture, I am hopeful and enthusiastic about our company's position and the future.

Matthew Klein, M.D., M.S., FACS
Chief Executive Officer

A message from our CEO

Who we are

MISSION STATEMENT

As a growing global company distributing treatments in more than 50 countries, our focus over the last 25 years has been about bringing more moments to our patients living with rare diseases and their loved ones. Our approach to corporate social responsibility is rooted in our commitment to patient advocacy, access to medicines, and advancing science.

Our science

PTC is a dream team of true pioneers. We translate science to transform lives. With intense cross-functional collaboration, unmatched expertise, and cutting-edge biotechnology platforms, we're urgently turning the latest scientific advances into meaningful treatments.

Our broad range of scientific platforms include:

- **Splicing** – Modulating splicing to control protein production
- **Bio-e** – Targeting oxidative stress and inflammation pathways to treat CNS diseases and cancer
- **Gene Therapy** – Targeted genetic therapies to treat rare CNS disorders
- **Nonsense Suppression** – Bypassing translation mutations to enable protein production

Our therapeutic areas

Since our inception, PTC has been an expert in RNA biology. Today, our biotechnology platforms have expanded, but harnessing the most promising scientific approach to target the root cause of a disorder has remained constant.

Neurology

- Amyotrophic Lateral Sclerosis (ALS)
- Angelman Syndrome (AS)
- AADC-d (Aromatic L-Amino Acid Decarboxylase Deficiency)
- Duchenne Muscular Dystrophy (DMD)
- Friedreich Ataxia (FA)
- Hereditary Transthyretin Amyloidosis (hATTR)
- Huntington's Disease (HD)
- Mitochondrial Disease Associated Seizures (MDAS)
- Spinal Muscular Atrophy (SMA)

Metabolism

- Familial Chylomicronemia Syndrome (FCS)
- Familial Partial Lipodystrophy (FPL)
- Phenylketonuria (PKU)

Oncology

- Diffuse Intrinsic Pontine Glioma (DIPG)
- Leiomyosarcoma (LMS)




Research & development

For 25 years, PTC has upheld a commitment to innovation using groundbreaking science to discover and develop treatments for patients living with rare disorders. We believe by using the newest technologies available, we can pioneer ways to treat these diseases and allow patients to share more moments with their families and loved ones.

PTC continues to make significant investments to expand its research and development programs with a cumulative investment of 67%* in 2022. We also leased a facility in Warren, N.J. to support internal research, clinical development, and commercialization of the company's growing pipeline of products.

* As a percentage of Business Operation Expenses (GAAP R&D + SG&A)



SPOTLIGHT ON Mountain View

Mountain View, Calif. is home to PTC's Bio-e platform, which targets oxidative stress and inflammation pathways to treat central nervous system (CNS) diseases and cancer. The platform utilizes expertise in electron-transfer chemistry to modulate key biological processes beyond the reach of current drug development approaches.

The origins of Bio-e began with a focus on pediatric mitochondrial diseases. The lead compounds from this innovative platform are vatiquinone (formerly PTC743) and utreloxastat (formerly PTC857). Today, two registration-directed studies are ongoing with vatiquinone: a Phase 2/3 trial in MDAS and a Phase 3 trial in Friedreich ataxia (FA). We're also conducting a clinical trial in amyotrophic lateral sclerosis (ALS) for utreloxastat.

Developing small molecule therapies for pediatric mitochondrial diseases remains a focus in Mountain View, but the research team is leaning in to its expertise to develop



Angela Minnella, who leads PTC's neuroscience and discovery research group, shares insights on how the team works together to develop small molecule therapies out of the Mountain View, Calif. facility.



molecules for adult neurodegenerative diseases like Parkinson's disease and ALS, as well as several oncology indications.

"It's really exciting that we have two programs in Mountain View that are now in clinical trials," says Jeff Trimmer, VP, Site Head – Mountain View & Head of External Research and Alliance Management. "We have all the necessary resources to successfully move our programs into the clinical phase and advance towards key milestones, which is a true testament to our mission of delivering more therapies to patients."



Products & pipeline

PTC is committed to improving the lives of patients through multiple products that are making a difference in the lives of patients and families. We have many promising product candidates in our pipeline. In our search for new treatments, we are continually investing in cutting-edge programs.



In 2022, PTC achieved several exciting product and pipeline milestones, which helped us reach more patients and drive progress in the study of our investigational treatments.

Our most noteworthy accomplishments include:

Clinical achievements




Initiation of **CARDINALS** study for **utreloxastat**



Initiation of **PIVOT-HD** study for **PTC518**



Initiation of **SUNRISELMS** trial for **unesbulin**



Completion of **Study 041** for **Translarna**



Completion of **FITE-19** study for **emvododstat**



Completion of enrollment for **MIT-E**

Regulatory achievements



Achieved **European Union (EU)** and **United Kingdom** approval for **Upstaza**



Achieved **Waylivra** approval in **Brazil** for the treatment of **FPL**



Filed type II variation for **MAA** for **Translarna** in **EU** and additional **global approvals**

Awards & Recognition

- ☆ **2022 Biotechnology Innovator of the Year** by BioTech Breakthrough
- ☆ Gene Therapy Center of Excellence recognized in the **New Good Neighbor Awards** by NJBIA
- ☆ Finalist in the **Pharma Industry Awards Ireland** for Biotech Company of the Year and Supply Chain Achievement Award
- ☆ Le Fonti Award winner for **Excellence of the Year** – Innovation & Biopharmaceutical Leadership



Patients

PATIENT ADVOCACY

A commitment to patient advocacy is a foundational hallmark of our company. Working with patients, families, those affected by rare disease, and non-profit organizations allows our patient relations team to better understand the patient experience and share those insights across PTC throughout the drug discovery and development process.

PTC has partnerships with more than **200 patient advocacy groups** to support individuals worldwide with rare diseases. Today, we have multiple products on the market that are making a difference in the lives of patients and their families with a growing number of product candidates in our pipeline. We continue to work with these advocacy groups to bring our therapies to patients.



Support for the rare disease community



Adam Peska



Lizanne Schreur



Patrick, a.k.a. "Tick"

#DuchenneCan. Our global social initiative campaign celebrates the stories of individuals in the Duchenne community whose abilities, strengths, and determination have inspired personal growth and progress, positive change in the community, and amplified the voice of Duchenne around the world.

- **Adam Peska**, a Boccia 2020 Paralympic gold medalist from the Czech Republic. Adam began playing Boccia at 12 years old before going on to become the second person with Duchenne ever to win a gold medal at the Paralympics.
- **Lizanne Schreur**, an aspiring screenwriter, and one of the ultra-rare women living with Duchenne. Lizanne moved to the U.K. as a

teenager and is currently studying television production at Ravenbourne University in London, where she has been involved with a number of onscreen productions and shows.

- **Patrick, a.k.a. "Tick"**, a professional performer and musician from Sao Paulo, Brazil, lives with Duchenne. [Patrick continues to overcome boundaries, showing that people living with Duchenne can be successful performers and reach their goals.](#)

Screen4Care. Screen4Care is a European research project aimed at significantly shortening the time it takes to diagnose rare diseases by utilizing genetic newborn screening and advanced analysis methods like machine learning. In 2022, PTC announced an innovative

research partnership with Screen4Care, which allows us to work alongside 36 international partners from academia, industry, and patient advocacy organizations to find solutions to shorten the path to diagnosis and find appropriate care for rare disease patients and their family.

Rare Talks: AADC Podcast. The Rare Talks: AADC podcast is a series focused on AADC deficiency (AADC-d) awareness and information with episodes aimed at healthcare professionals as well as parents and caregivers. Guests include leading experts to discuss key AADC-d topics, from signs and symptoms to navigating through the appropriate tests to confirm a diagnosis.


#DuchenneCan



Clinical trials

We know that when it comes to rare disorders, each day matters, and every moment counts. It's why we are committed to making progress in rare disease through clinical trial research, each and every moment of every day.

PTC has multiple registration-directed clinical trials that hold hope for many rare disease patients.



Support for patient communities and access to care

Patients are at the center of everything we do at PTC. In 2022, we strategically expanded our global footprint with the opening of new PTC offices in Warsaw, Poland and Tokyo, Japan to ensure we help more patients in key geographic areas have greater access to our therapies. We also continued to support numerous organizations that assist patients with rare diseases to these causes, while championing patient voices through our #DuchenneCan initiative and MyVibe™ program to raise awareness about broadening patient access to treatment globally.



We continue to offer programs that help patients, including free genetic testing, guidance through the logistical, financial, and insurance process for using PTC products, and enable cost-effective solutions for multiple siblings in a family who need access to our medicines.

STRIVE™: For more than eight years, PTC's STRIVE (Strategies to Realize Innovation, Vision and Empowerment) Awards Program has provided 39 grants to patient advocacy organizations in 20 countries to help realize meaningful projects that address the unmet needs of the rare disease community. The STRIVE program's global initiatives make a positive impact through increased awareness or diagnosis of Duchenne, advanced education, improved quality of life of patients, improved patient access to medical care or fostering of future patient advocates. In 2022, we were proud to recognize four winning initiatives and communities who have continued to show uninterrupted resilience for the Duchenne community around the world:

- **ACDM (Associação Cearense de Distrofias Musculares)**. Using the STRIVE grant, ACDM will be launching PROJECT FACILITATE, which aims to ensure students with Duchenne have their needs met while at school.
- **Action Duchenne**. Action Duchenne helps to support and empower people with Duchenne as they transition to adulthood. With STRIVE funding, the organization intends to offer a series of skills-based training courses to help young members become independent adults.
- **MDA Hellas – Muscular Dystrophy Association of Greece**. With the help of the STRIVE grant, MDA Hellas, an organization dedicated to improving the quality of life of people with Neuromuscular Disorders (NMD) in Greece, will produce and premiere a short film focused on sexuality and sex life with Duchenne. The film will be accessible to the global Duchenne community and will offer realistic and much-needed insight into a topic which has long been viewed as taboo.

- **Neuromuscular Disorders Association of Turkey/KASDER**. Having first won the STRIVE grant in 2018, the Neuromuscular Disorders Association of Turkey (KASDER) set up an online psychological support system for Turkish-speaking individuals with Duchenne around the world. Since then, more than 500 support sessions have been run for 47 Duchenne patients and their relatives. Now KASDER plans to expand their offering to provide 50 people with weekly access to the service, conduct more than 1,500 sessions annually, and train an additional 30 psychologists on how to best support individuals with Duchenne.



Insightful Moments™: Insightful Moments is our community education series of resources created to support patients with rare diseases and their families. Through live webinars, animated videos, roadmaps summarizing the materials, and audio recordings, the series covers a wide range of topics, including drug discovery and development, navigating clinical trials, insurance, government programs, and holistic inspirations. In 2022, we introduced a new podcast series called MyVIBE™: My Voice is Inspirational, Brave and Empowering. The series gives a voice to patients, caregivers, families, and friends to share their unique stories and journey about living with a rare disease.



Insightful Moments™



My VIBE™:

My Voice is Inspirational, Brave and Empowering

Compassionate care

PTC is committed to providing access to our treatments for patients around the world. Since 2013, we have worked with certain patients and their physicians to provide products free of charge via our Compassionate Use program in areas globally where access to our products may not yet be available. We engage with appropriate local health agencies to provide access to these patients while we work to make our products available to all who could benefit from our treatments.




People

THE PEOPLE OF PTC

Our culture is to make every day count; to care for each other, our community, and for needs of our patients; to be critical, not cynical, of what we do, but not of each other; we strive every day to be better than we were the day before; we want to be part of an important cause and strive to achieve great accomplishments. We are more fearful of not daring to do great things than of failing.

Our collective belief is that the impossible is within reach. This, coupled with our nimble and entrepreneurial spirit, powers our pursuit. For us, changing the course of rare diseases isn't a job, it is our purpose. At PTC, we work as one to make the impossible possible.

PTC Expectations





Talent planning

Careers with purpose

PTC has established itself as a global biopharmaceutical company that delivers transformative therapies for people living with rare diseases. For 25 years, we have been harnessing our scientific platforms to create new therapies that address the underlying cause of the disease and deliver on our promise to create more moments for those who count on us. Together, the difference we can make is limitless.

Stats & Figures

More than
1,400
employees

20 offices
worldwide,
distribute
treatments in
50

90%
Employee
retention
rate

Employee
advancement/
promotion rate
19.63%

Moment Makers

Ensuring employees feel valued and are recognized for their contributions both professionally and personally is an integral part of the culture at PTC. Our people often go above and beyond and have many stories, experiences, and moments that make a difference and impact the lives of our patients and colleagues. Their stories represent the great work being done at PTC, while epitomizing our values, passions, and expectations. PTC regularly highlights employee stories within the organization through a video series, Moment Makers.



In 2022, PTC released its Moment Makers episode featuring Anderson Freitas, Senior Director of Market Access in Latin America to lend an eye-opening perspective of the challenges of bringing therapies to patients living in remote areas of Brazil. By staying true to the values of our OnePTC mindset, the team has been able to achieve great success in the region.



Global onboarding






PTC recognizes the importance of establishing appropriate new hire expectations on our culture, values, and behaviors when new colleagues join the company. The cross-functional Global Onboarding Committee's mission is to ensure a quick and successful onboarding experience for all new hires. The team has established global standards, resources, surveys, and response teams when opportunities for improvement are identified. PTC also leverages an Onboarding Buddy program, which pairs new hires with an experienced colleague to help welcome and encourage them in their first three months by offering advice, guidance, and resources about the company. In 2022, we successfully onboarded hundreds of new employees and contractors globally.











Benefits & Wellbeing

Employee Benefits

PTC offers a wide variety of benefit options to meet the diverse needs of our employees. We are committed to ensuring that our benefits program offers meaningful choices plus valuable resources to support the moments that matter most. Our benefits evolve each year and are designed to ensure that our employees are healthy and protected, now and in the future.

Our comprehensive benefits in the U.S. include:

-  Medical, Dental & Vision Insurance
-  Dependent and Health Flexible Spending Accounts and Health with Company Contribution
-  Savings Accounts
-  Retirement Plan with Company Match
-  Income Protection Including Life, Disability, and Child Bonding Benefits

-  Employee Stock Purchase Plan
-  Company-Wide Equity Awards
-  Family Planning Benefits
-  Tuition Reimbursement
-  Remote Work/Schedule Flexibility
-  Time-Off Programs
-  Peer Recognition Program
-  Global Wellbeing Program
-  Caregiver Program for Children with Special Needs
-  Global Employee Assistance Program (EAP)

Outside of the U.S., we also offer many of these benefits, as well as others consistent with local expectations for our industry in addition to applicable legal requirements.

“While I was traveling, I needed help with an important issue I faced. Fortunately, I remembered I could contact EAP because they are available 24 hours, 7 days a week, and they have experts across the globe on many different topics. I got a quick response from an expert who helped me evaluate alternatives for resolving that issue. I highly recommend this important, and very helpful benefit.”

—PTC Employee on PTC's Global EAP Benefit

Employee Relief Fund

PTC offers a global non-profit charitable fund designed to help employees facing a financial hardship with a tax-free grant in their time of need, whether it's immediately after a natural disaster, during a pandemic, or due to an unforeseen personal hardship. The PTC Employee Relief Fund relies primarily on individual donations from employees. In 2022, we were fortunate to receive the following contributions:



Nearly **\$17,000** in employee contributions were made in 2022



Donations from all around the world, including **Germany, Ireland, Sweden, Switzerland, United Kingdom, and the United States**



More than **\$19,000** in grant money was awarded to employees in 2022



Building a strengths-based learning culture

At PTC, we believe in supporting our employees individually, as leaders, and as team members to be the best they can be. We are committed to investing in leading-edge systems that will strengthen and further develop our people both professionally and personally.

Last year, our employees worldwide engaged in nearly 9,500 hours of development training across all of PTC's programs and platforms. All employees have access to a wide range of learning opportunities, from assessment programs that help them realize their top strengths and behavioral work styles, to robust learning platforms and content libraries that can enhance their career and management skills, to personalized mentorship coaching programs for professional growth.

Growing leadership from within

With strong talent comes the need for even stronger leadership training, and PTC has instilled various programs to support employees in becoming the next-generation company leaders. Our key initiatives involve leaders from across the company, including the Executive Committee (EC), key senior leaders, and Board Members.



**MENTORSHIP ROUNDTABLE
BOARD OF DIRECTORS**



Enriching the pipeline of future leaders: PTC's Emerging Leaders program



The PTC Emerging Leaders is a program that Hege Sollie-Zetlmayer, SVP, Human Resources initiated back in 2021. “I wanted to create a program that was tailor-made for PTC, for the culture we have and want to keep at our company,” says Hege. “The goal was to create a community of leaders within PTC that will lead to well-balanced diversity at the senior most levels of the company in the future. And to address a key question early on: is being a leader the right choice for me?”

When the Emerging Leaders (EL) planning team started on this journey, they knew the end result needed to be a program specifically made for future leaders of PTC: one that was built around PTC's Expectations, each individuals' CliftonStrengths, and how to lead in an entrepreneurial, co-creating, tight-knit culture like PTC's. The team wanted to learn from the rich experiences of the company's senior leaders, using the power of stories as valuable tools and techniques to create engaging, inspiring, and determined future PTC leaders. For Hege, it was also essential to create a community of future leaders within PTC that would one day lead to a healthy range of diversity at the top as these emerging leaders advance at the company.

In the inaugural launch of the Emerging Leaders program, 15 employees were selected to participate and divided into four study teams with Executive Committee members in place as each team's sponsor. Each participant also had a certified CliftonStrengths coach throughout the whole journey.

Over the span of six months, the four study teams proposed and worked on projects, which were approved and endorsed by the EC, and will be implemented by the Emerging Leaders in the future. These projects included: organizing a PTC Day for all employees, developing a toolkit for Early Career Professionals, creating a “First Friend” program for PTC's Fellow program graduates, and improving PTC's reputation by enabling a team of brand ambassadors.

Following the success of the first cohort, the EL planning team soon moved forward with forming the next class—with even more participants—to continue enriching and growing the future leaders of PTC.

“The quality of the program has exceeded all my expectations,” says Hege. “I'm looking forward to seeing the full impact of the program in a few years as the participants take on broader roles and more responsibilities in the organization.”

“We created a program fit for PTC, for the culture we strongly believe in, that we want to keep and rally around as described in our PTC expectations.”

—Hege Sollie-Zetlmayer, SVP,
Human Resources



Throughout her eight years at PTC, Adele Nogueira, Senior Manager, Client Experience, shares how the Emerging Leaders program has given her new opportunities to grow and how it’s helping to shape her future.






Emerging Leaders At-A-Glance



Number of cohorts launched and completed: 2



Number of participants in the program year-to-date: 35



Number of hours dedicated: 2,450



Goals and performance

At PTC, corporate goals and employee performance are managed through the system of OKRs, or “Objectives and Key Results,” pioneered at Intel by Andy Grove and widely used in the technology industry. OKRs from the CEO on down are transparent to all employees through an internal system we developed and are refreshed and assessed on a quarterly basis.

Community

At PTC, we take pride in our collaborative culture. Our Culture & Community team seeks to build strong communities through improved relationships, empathy, and the ability to work with people from all walks of life.

Our mission is to collaborate with cross-functional partners and create intentional efforts to connect and engage with employees who want to find community and apply their passion to make a difference both in and out of the workplace.






Global equality, diversity, and inclusion

Our Equality, Diversity, and Inclusion (ED&I) program focuses on awareness, outreach and developing our talent pipeline. PTC recognizes that when employees understand and celebrate one another as whole persons, especially our differences, we are enabled to perform as teammates at the highest level.

PTC's Culture & Community team helps cultivate a supportive environment led with kindness and various opportunities for engagement through our Employee Resource Groups (ERGs) and Business Resource Groups (BRGs).

In 2022 PTC enjoyed an exciting year of awareness, talent development and opportunities, and outreach through the combined efforts of our global employees led by our ERGs and BRGs. More than **820** or **56%** of our employees participated in **172 events** meetings and events throughout the year, which included:



Employee Resource Groups

Our seven ERGs are employee-led groups that foster a diverse and inclusive workplace aligned with underrepresented and minority communities. The ERGs offer a safe place for our employees to have conversations about social issues, celebrate cultural observances, and to grow. Participation in ERGs is open to all employees who would like to advocate for that community's mission and goals. Approximately 450 employees worldwide participated in at least one ERG group by the close of 2022.

The communities represented by our ERGs are:

1. Asia Pacific Islander Alliance
2. Black Empowerment Council
3. Women + International Network
4. PTC Pride – Lesbian, Gay, Bisexual, Transgender, Queer +
5. Organization for Hispanic/Latinx Allies
6. South America & Mexico Multicultural Alliance
7. Multicultural Alliance Group of Inclusive Communities

Business Resource Groups


PTC's BRGs are voluntary, employee-led groups which seek to foster a diverse, supportive workplace environment and include members who identify with several of our ERGs. The BRGs are aligned with our strategic business goals versus an underserved or marginalized community. They are focused on future growth of our employee population in key areas, such as maintaining low attrition and attracting and developing those who are early in their career.

Our three BRGs currently include:

1. **Early Career Professionals (ECP).** The ECP group provides those with up to 10 years of experience access to training, networking, and career advice. Collaborate with other ECPs at PTC and learn more about what it means to be an Early Career Professional.
2. **Balance.** Balance seeks to support employees who want to achieve success in their careers while also maintaining a fulfilling personal life – in other words, the recognition and promotion of "being your whole self".
3. **Women of Color in Pharma (WOCIP).** WOCIP empowers women of color (the most underrepresented community in pharma) to excel in their personal and professional development, to transform their pathway and the pathway of others by creating a nurturing and safe environment to self-reflect and discover innovative and leadership opportunities within PTC.

Employee Demographics

**Based on data for employees in the U.S., due to individual geographic privacy and employment laws which prohibit collection of this information outside of the U.S.*



Global employee outreach

We are committed to not only caring for our patients but striving to meet the needs of people in our communities. In 2022, PTC provided funding to support a wide array of causes. Our Global Outreach Committee helps orchestrate company-wide volunteer and giving opportunities that are guided by five fundamental pillars: **students, community needs, patients, planet/environment**, and **disaster relief**.



Global outreach efforts in 2022

Students

- We issued a grant to **Students2Science** to support **1,300 students at Passaic Academy of Science and Engineering**, a six-year-old partnership in N.J.
- Our Mountain View, Calif. team ran a similar outreach effort by supporting the award-winning **Science from Scientists (SciSc)** program to bring hands-on experiential science education to elementary and middle schools in the California Bay Area.
- To ensure **underprivileged children in N.J.** were prepared for a successful new school year, PTC employees collected school supplies and backpacks for approximately **160 students** – and then PTC doubled it.
- Our teams across the globe arranged to **donate more than 100 refurbished PTC laptops** to support students in need in **Brazil, Argentina, Switzerland, Ireland, and the U.S.**

Mountain View Partners with Science from Scientists for the 2022-2023 School Year
Our Childrens' Literacy Matters!

- PTC is supporting award winning Science from Scientists (SciSci) to bring hands-on experiential science education to elementary and middle schools
- The SciSci model is to bring real scientists into the classroom to deliver challenging and inspiring lessons that change students' appreciation for the topic

PROGRAM IMPACT FOR 2022-2023 → 1,600 STUDENTS IN UNDERSERVED COMMUNITIES

To learn more go to: www.sciencefromscientists.org



Community needs

- PTC Switzerland was a proud sponsor and supporter of the **Powerchair Hockey World Cup**, a global championship sporting event for people with physical disabilities.
- The **U.S. team** undertook a notable effort to **pack more than 10,000 meals** to benefit the global organization, **Rise Against Hunger**.
- In South America, **PTC Brazil** collected **warm coats and blankets for those in need** in Sao Paulo, while **PTC Colombia** created boxes of love with **groceries and gifts** for local families.
- Our team in **Hopewell** collected hygiene products, pantry items, and new clothes for the **Trenton Area Soup Kitchen** as well as holiday gifts for **needy children across the U.S. and Mexico**.




Campanha do Agasalho 2022: Muito obrigado!

Gostaríamos de agradecer a todas e todos que conseguiram separar um momento para participar de nossa Campanha do Agasalho 2022, aquecendo a vida de diversas pessoas neste inverno!

Para quem ainda tiver interesse em apoiar a CROPH - entidade que auxilia pessoas em situação de vulnerabilidade social -, as doações podem ser feitas via PIX:

Chave PIX - CNPJ: 43.473.487/0001-32
 Coordenação Regional das Obras De Promoção Humana
 Banco Bradesco
 Agência: 2003
 C/C: 24963-7

Comitê de Responsabilidade Social




Patients

- Our **Hopewell Community Team** hosted a volunteer event where more than 100 employees came together to build 140 bears for children with rare diseases under the **RARE Science Rare Bear Program**.
- PTC was a sponsor for the **rideATAXIA** fundraising event hosted by the Friedreich's Ataxia Research Alliance to raise awareness and funding in support of **FA research**. In addition to being a sponsor, PTC employees participated in the day-long bike ride event last September in King of Prussia, Penn.
- In support of DMD patients in Ireland, PTC's **Stephen Keane** embarked on a 6-day, 761 km cycling ride as part of the **Paris2Nice** event, raising 3,005€ to donate to **Duchenne Ireland**, a patient organization and registered Irish charity for advancing research and support networks for **DMD**.
- **PTC Switzerland** donated laptops to **Mathilde Escher Stiftung**, a foundation dedicated to helping people with DMD live an independent, autonomous life.



Planet

- Our **Hopewell Community Team** partnered with the **Watershed Institute** to volunteer at two stream clean-up efforts and raised financial support by participating in a 5k run.
- In **Switzerland**, PTC employees teamed up to plant 100 oak trees in partnership with **OneTree Planted** and **Almighty Tree**. The trees were planted to help combat climate change and prevent biodiversity loss for generations to come.

Emergency relief

- In response to an **act of violence** against an Irish schoolteacher jogging in a park who was attacked and killed, **PTC matched the donations** of employees who provided financial support to an Irish organization addressing violence against women.
- As the crisis in **Ukraine** unfolded, PTC donated to a local organization supporting displaced **DMD patients**, as well as to the **DIG PKU Ukrainian Relief** program.
- PTC provided funding to the United Nations to **provide relief to refugees**, as well as to an organization in Spain that sponsors MDs traveling to Africa who provide **free medical care** to people in need.
- PTC responded to the damaging hurricanes in **Puerto Rico** and **Florida** by matching our **employees' donations** to relief efforts.



Community enrichment

PTC isn't just another pharmaceutical company. Here, the difference we can make together is unmatched. We believe in creating programs that will enrich the overall biotech and healthcare communities to be ever better, whether that's by mentoring future professionals of our industry or proactively building relationships with elected government leaders to ensure that the voice of PTC employees and its patients are heard on issues that most deeply affect us.

Our PTC **Talent Pipeline Program (TPP)**, for example, was launched to help create opportunities for new graduates during a time when many talented and hardworking students were rightfully worried about being able to enter the workforce. The program entails a one-year global fellowship for individuals at the beginning of their careers to gain real-world experience in the biopharmaceutical industry and related professions, including research, finance, commercial, compliance,

quality, legal, information technology, and communications. TPP focuses on supporting those at the beginning of their careers with an immersive program that provides mentorship, job coaching, career counseling, and leadership training. To date, our TPP has had **53 Fellows** from around the world complete the program, with **38 more students** currently in the middle of a fellowship. Since launch, **36 Fellows** have transitioned into full time positions at PTC.

Through the **PTC Political Action Committee (PTC-PAC)**, employees can help give us a voice to influence policies related to patient access to medicines, government reimbursement, the U.S. patent system, fostering an innovation-friendly business environment, the role of the federal government in research, and so much more. PTC-PAC brings the voice of PTC employees and patients to the forefront of public policy discussions.



Environment

GREEN OPERATIONS

As a science-based company, we understand the impact people have on the environment. We strive to be good citizens of the world and make change for a better planet, whether it's with EV charging stations at our offices or robust energy-efficiency measures.



Our key efforts in 2022 include:



Confirmed our laboratories meet all environmental standards and have consistently passed inspections by multiple government authorities.



We have replaced lightbulbs in all buildings at our corporate headquarters with LED lighting.



Completed installation of charging stations for electric vehicles in all N.J. facilities.



Installed water cooler stations at all N.J. facilities to encourage the use of tap water in lieu of using bottled water.



We encourage our employees to use reusable water bottles, cups, plates, and silverware to reduce the use of paper or plastic.



More than 20% of electricity used at our South Plainfield office is generated through wind power.



The Bridgewater, N.J. facility's participation in our recycling program yielded 36.59 tons recycled at a 59.8% recycling rate.



We are actively targeting LEED certification for our new Warren site and all new facilities, a recognized symbol of sustainability achievement and leadership.

Sustainability efforts

We continuously look for ways to enhance and ensure our sustainability efforts are compliant with environmental requirements and regulations and encourage employee actions which are environmentally friendly.

Last year, PTC officially formed a Global Environmental Team whose mission is to engage in initiatives with local regional teams to make positive impacts on our environment both at work and at home.

The team will continue to build on the momentum of previous activities throughout the company that has included a \$10,000 grant to support the Hopewell Watershed Institute Fest, planting trees, repurposing older technology, and improving PTC's ongoing recycling efforts in our labs and offices.





Ethics & compliance

COMPLIANCE PROGRAM

Our Global Compliance Program incorporates the elements of an effective compliance program in accordance with the “Compliance Program Guidance for Pharmaceutical Manufacturers,” developed by the U.S. Department of Health and Human Services, Office of Inspector General (“OIG”) and other laws and regulations that govern our industry.

The program is designed to help prevent non-compliance with company policies and the laws and regulations applicable to the pharmaceutical industry, as well as detect and correct non-compliance.

PTC provides multiple channels for asking questions and raising potential compliance concerns. Regular compliance training for all applicable employees is required as part of the program. Compliance policies, training, and education are tailored to the audience and translated into local language as necessary.

Compliance App

In 2022 we introduced a new Compliance app to serve as a one-stop-shop for important Compliance information that streamlines several key resources, including:

- Code of Business Conduct and Ethics
- Confidential Hotline
- Grants & Donations
- HCP/HCO Engagements
- Transparency & Reporting
- Third Party Due Diligence
- Privacy and Data Protection
- Country-specific guidance

Code of business conduct & ethics

PTC introduced a refreshed Code of Business Conduct and Ethics in 2022 for employees to help the company best fulfill its commitment to patients while acting with integrity. The Code contains principles and standards that guide PTC's business behavior throughout the world.

Every employee of PTC is responsible for doing the right thing to support the Company's culture and conduct business with integrity. The Code is one of the ways PTC communicates its clear expectations set for employees.

Confidential Hotline

Our confidential hotline can be accessed 24 hours a day, 7 days a week and is offered in multiple languages. Concerns may be reported by phone or online. This hotline is monitored by a third-party and all reports to it are followed up in accordance with our policies.



Privacy policies & cybersecurity

The objective of PTC's cybersecurity program together with the data protection and privacy program is to ensure the protection of all confidential data which includes, but is not limited to, sensitive personal data, directly or indirectly identifiable personal data of patients, healthcare professionals, employee and third party data. Confidential data subsets include, but are not limited to human resource data, web visitors' data, clinical trial data, operational data, financial data, and intellectual property. PTC takes appropriate steps to protect this data from loss, misuse, and unauthorized access, disclosure, alteration, or destruction. We respect individual privacy rights and apply appropriate data protection measures to respect these rights. Any concerns related to a potential or actual breach of personal information are considered serious in nature and are thoroughly investigated and notifications provided as required by local law.

Our Chief Information Officer is part of the Compliance Committee, which oversees the outcome of cybersecurity investigations, and has direct access to our CEO and Board for this purpose without any requirement to consult with management in advance. PTC follows cybersecurity industry best practices as outlined in The National Institute of Standards and Technology (NIST) through the implementation of technical, administrative, and operational controls. These controls create

multiple defensive layers to protect sensitive data by ensuring confidentiality, integrity, availability, and resilience of processing systems and services. In cases of personal data breaches, the Compliance Officer is fully involved and approves necessary external notifications as required.

Everyone in the company has a role to play in protecting and securing confidential and personal information. This is achieved through awareness campaigns, communication and multiple learning opportunities covering topics that include, but are not limited to legislative and external industry updates, email use, internet browsing, and sensitive data handling. PTC maintains an enterprise-wide policy and standards that guide the collection, use, maintenance, and protection of personal data and consider the legal and regulatory requirements in countries where we do business. These standards include, but are not limited to:

- Anonymization
- Data Minimization
- Asset Management
- Authentication
- Encryption
- Identity Management
- Access Control
- Physical Access
- Pseudonymization Third-Party Risk Mitigation
- Personal Data Breach Notification

Board of Directors

PTC's Board of Directors works with our management team to ensure that our culture is conducive to a productive and healthy work setting and that the company approaches corporate governance, environmental and social issues in a way that is consistent with our culture.



Michael Schmertzler
Chairman

Mr. Schmertzler has served as a member of PTC's Board of Directors since 2001 and as the Chairman of the Board since 2004. He joined PTC's Board after leading the Series A investment in the company as Co-Head of Credit Suisse First Boston Equity Partners. Mr. Schmertzler is also currently a director of Berryville Holdings (a cybercommunications security software development company); Dispel (a secure remote access provider protecting critical infrastructure); and SHY Therapeutics (a small molecule therapeutics company).



Stephanie S. Okey, M.S.
Former SVP, Head of North America,
Rare Disease – Genzyme

Ms. Okey has served as a member of PTC's Board of Directors since December 2018. She has more than 30 years of experience in the biopharmaceutical industry, and most recently served as the Senior Vice President, Head of North America, Rare Diseases and U.S. General Manager, Rare Diseases at Genzyme, A Sanofi Company. Ms. Okey has significant experience in pre-launch, launch, and commercialization of rare and orphan disease products, as well as large market products.



Allan Jacobson, Ph.D.
University of Massachusetts
Chan Medical School

Dr. Jacobson is a co-founder of PTC and is the Gerald L. and Zelda S. Haidak Distinguished Professor of Cell Biology at the University of Massachusetts Chan Medical School. He has served as a member of the PTC Board of Directors since the company's inception in 1998, previously served as Chairman of the Board of Directors from 1998 to 2004, and has served as Chairman of the Scientific Advisory Board since 2000. He is the co-recipient of the 2023 Gruber Prize in Genetics.



Matthew B. Klein, M.D., M.S., FACS
CEO, PTC Therapeutics, Inc.

Dr. Klein is CEO and President of PTC Therapeutics. Prior to becoming CEO in 2023, Dr. Klein served as chief operating officer. Prior to joining PTC, Dr. Klein was chief executive and chief medical officer of BioElectron Technology Corporation, a biotechnology company focused on the development of redox-active small molecules for mitochondrial disease and related disorders of oxidative stress. Before joining BioElectron, Dr. Klein was the Auth-Washington Research Foundation chair of restorative burn surgery at the University of Washington. He received his bachelor's degree from the University of Pennsylvania where he graduated summa cum laude, before earning his doctorate of medicine with honors from Yale University.



Emma Reeve
Independent Board Director

Ms. Reeve is an accomplished biopharmaceutical executive with more than 25 years of global financial experience across pharmaceutical, medical device, and biopharma companies. Most recently, she served as Chief Financial Officer of Constellation Pharmaceuticals, Inc., a development-stage oncology company, prior to its acquisition by MorphoSys AG in 2021. Ms. Reeve led Constellation's initial public offering in 2018 and raised more than \$700 million for the company during her tenure.



Mary L. Smith
The VENG Group

Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a \$6 billion division of the U.S. Department of Health & Human Services and system of hospitals providing healthcare to more than 2 million Native Americans in the U.S. She currently serves as Vice-Chair at the VENG Group where she consults clients on business development, strategy, healthcare, and corporate governance. Additionally, Ms. Smith founded the Caroline and Ora Smith Foundation, which sponsors, supports, and trains Native American girls in science, technology, engineering, and math.



David P. Southwell
Former CEO, TScan Therapeutics

Mr. Southwell has served as a member of our Board since 2005. From October 2018 to March 2023, he served as CEO and a member of the Board of Directors for TScan Therapeutics, Inc., a Nasdaq-listed biotechnology company. He served as President and CEO and member of the Board of Directors of Inotek Pharmaceuticals from August 2014 until its merger with Rocket Pharmaceuticals in January 2018. Mr. Southwell currently also serves on the Board of Directors of Rocket Pharmaceuticals.



Glenn D. Steele, Jr., M.D., Ph.D.
Chairman of GSteele Health Solutions

Dr. Steele serves as Chairman of GSteele Health Solutions, an independently operated venture launched to help healthcare organizations create value and improve quality. He is the former President and CEO of Geisinger Health System (2001-2015), an integrated health services organization nationally recognized for its innovative use of the electronic health record and the development and implementation of innovative care models. A prolific writer, he is the author or co-author of more than 500 scientific and professional articles.



Alethia Young
Chief Financial Officer, Graphite Bio

Ms. Young has more than 20 years of experience in the biopharmaceutical industry. In her current role, Ms. Young oversees the company's finance, investor relations and corporate communications functions, and plays a key role in overall corporate strategy. Previously Ms. Young served as senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering large cap and small-mid-cap biotechnology companies.



Jerome B. Zeldis, M.D., Ph.D.
NexImmune, Inc.

Dr. Zeldis has served as a member of PTC's Board of Directors since September 2012. He is currently the Executive Vice President of NexImmune Corporation. Until June 2016, Dr. Zeldis served as Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation, a public biopharmaceutical company, where he was employed since 1997. Dr. Zeldis also serves on the Board of Directors of Soligenix and BioSig Technologies.